<DOC>
	<DOCNO>NCT00008268</DOCNO>
	<brief_summary>RATIONALE : Melphalan colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood . PURPOSE : Phase II trial study effectiveness melphalan combine filgrastim stimulate peripheral stem cell patient multiple myeloma .</brief_summary>
	<brief_title>Melphalan Filgrastim Stimulate Peripheral Stem Cells Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety efficacy melphalan use filgrastim ( G-CSF ) stem cell mobilization patient multiple myeloma . - Analyze mobilization regimen affect parameter stem cell ( CD34+ ) mobilization collection patient . - Determine mobilization regimen affect disease status clonotypic ( i.e. , tumor cell ) contamination stem cell component patient . OUTLINE : Patients undergo peripheral blood stem cell ( PBSC ) mobilization consist melphalan IV day 1 filgrastim ( G-CSF ) subcutaneously begin day 2 continue PBSC collection complete . Patients follow 1 month . PROJECTED ACCRUAL : A total 11-32 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Must receive induction therapy within past 3 month Chemoresponsive disease Greater 50 % reduction monoclonal paraprotein reduction marrow plasma cell infiltrate great 50 % reduction marrow plasma cell infiltrate disease nonsecretory No symptomatic pleural effusion Eligible stem cell transplantation PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 ( ECOG 3 allow due bone disease neuropathy ) Life expectancy : Not specify Hematopoietic : Platelet count least 150,000/mm^3 Hepatic : Bilirubin great 2.5 mg/dL Renal : Creatinine great 2.5 mg/dL OR Creatinine clearance great 51 mL/min Cardiovascular : No symptomatic cardiomyopathy No medically document symptomatic cardiac arrhythmia within past 60 day No New York Heart Association class III congestive heart failure No myocardial infarction within past 6 month Other : No concurrent medical condition would preclude study No uncontrolled infection No active malignancy within past 5 year except nonmelanoma skin cancer Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior stem cell mobilization transplantation Chemotherapy : See Disease Characteristics No 200 mg prior oral melphalan Endocrine therapy : Not specify Radiotherapy : No 3000 cGy prior radiotherapy myeloma Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>